Bod Science has released further positive results from a pharmacokinetics (PK) study of its Aqua Phase technology showing six times greater bioavailability than oil-based CBD.

The ethics-approved Phase 1 study enrolled 12 healthy volunteers who were fasted and dosed with either Aqua Phase CBD 100mg or CBD 100mg in oil in highly controlled conditions.

Analysis showed bioavailability improved by more than 530% (6.3 times), while maximum concentration was 270% (3.7 times) greater than oil-based CBD. Peak concentration was reached in 2.5 hours compared to six hours for oil.

Bod Science CEO Jo Patterson

An initial study, completed in July 2023, assessed the bioavailability of CBD complexed with Aqua Phase in capillary blood, while the latest research tested the technology in venous blood. 

Data from the studies demonstrated consistent results, although significantly increased bioavailability was seen in the venous study. Bod’s research and development work to support the commercialisation of the technology is now complete.

It said the outcomes “support the commercial opportunities of the technology as a preferred oral-dose format, solving solubility and bioavailability limitations of water-hating molecules”.

CEO Jo Patterson added: “We are pleased with the results from this second PK study as they further support the exciting properties of Aqua Phase as a unique product delivery process technology. 

“The results verify the value proposition. Aqua Phase holds a broader opportunity for drugs that have solubility and bioavailability limitation, not being limited to the cannabis sector.”

Bod flagged the pharmaceutical, nutraceuticals and beverage markets as other potential commercial opportunities for the technology, which it acquired from two UK scientists for A$5 million in a deal first announced in August 2022.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment